Home Health & Wellness Study Finds Metformin Manages Gestational Diabetes Safely

Study Finds Metformin Manages Gestational Diabetes Safely

Reading Time: 2 minutes

Recent research sheds light on the use of metformin during pregnancy, particularly for managing gestational diabetes mellitus (GDM). The study, published in the journal Endocrine, offers a comprehensive analysis of metformin’s impact on maternal and neonatal outcomes. With GDM rates climbing globally, understanding effective and safe treatment options is critical for both mothers and their offspring.

Gestational diabetes has become increasingly prevalent, now affecting approximately 16.7% of pregnancies worldwide. The condition poses numerous risks, including spontaneous abortion, pre-eclampsia, foetal anomalies, and neonatal complications such as hypoglycemia and respiratory distress syndrome. Traditionally, insulin has been the standard treatment for GDM, but its limitations, including the risk of hypoglycemia, weight gain, and the need for injections, make oral medications like metformin an attractive alternative.

The review sought to assess the effectiveness and safety of metformin in pregnant women with GDM, type 2 diabetes mellitus (T2DM), and polycystic ovary syndrome (PCOS). The findings are based on a thorough analysis of randomised controlled trials (RCTs) and meta-analyses.

Metformin consistently showed a reduction in maternal weight gain compared to insulin. This reduction is crucial, as excessive weight gain is linked to increased pregnancy complications. The studies reviewed indicated a weight difference ranging from 0.47 kg to 1.8 kg less in women treated with metformin.

Metformin demonstrated comparable or superior glycemic control to insulin, measured by various glucose metrics, including glycated haemoglobin (HbA1c) and fasting, postprandial, and random blood glucose levels. The ongoing EMERGE trial continues to explore the early initiation of metformin for GDM management.

While some women required additional insulin to achieve target glucose levels, the need varied significantly across studies. In the largest trials, a significant portion of women in the metformin group did not require supplementary insulin, highlighting metformin’s efficacy in many cases.

Metformin use was associated with a lower incidence of hypertensive disorders such as pre-eclampsia. The proposed mechanisms include metformin’s pro-angiogenic effects and anti-inflammatory properties.

Contrary to insulin, metformin was linked to fewer caesarean deliveries. This outcome is likely due to better glycemic control and lower maternal weight gain, which reduces the risk factors for caesarean sections.

Neonates born to mothers who used metformin tended to have lower birth weights and a reduced incidence of macrosomia. However, the rates of small-for-gestational-age (SGA) and large-for-gestational-age (LGA) infants were similar between the metformin and insulin groups.

Metformin was associated with a reduced risk of neonatal hypoglycemia compared to insulin. This finding is significant, as hypoglycemia in neonates can lead to severe complications if not managed promptly.

Although the indication for metformin use and the characteristics of the study population had a significant impact on this outcome, there was a slight increase in preterm births among metformin users.

The study highlighted potential concerns about altered foetal programming, which may predispose children to obesity and metabolic syndrome in adulthood. These long-term effects are still under investigation and warrant further research.

The safety of metformin, especially regarding its transplacental transmission, remains a critical concern. Metformin crosses the placenta, and its concentrations in umbilical cord blood can be substantial. But studies have not shown an increase in major congenital anomalies with metformin use. Researchers continue to explore the implications of metformin’s effects on foetal growth and nutrient bioavailability.

Metformin presents a viable alternative to insulin for managing GDM and other pregnancy-related hyperglycemic conditions. Its advantages include effective glycemic control, reduced maternal weight gain, and a lower risk of hypertensive disorders and neonatal hypoglycemia. Despite these benefits, concerns about potential long-term effects on offspring health persist. Therefore, ongoing research is essential to fully understanding the benefits and risks of metformin use during pregnancy.

© Copyright 2014–2034 Psychreg Ltd